Nara, Japan
Nara, Japan

Sharp Corporation is a Japanese multinational corporation that designs and manufactures electronic products. Headquartered in Abeno-ku, Osaka, Japan, Sharp employed 50,253 people worldwide as of March 2014. The company was founded in September 1912 and takes its name from one of its founder's first inventions, the Ever-Sharp mechanical pencil, which was invented by Tokuji Hayakawa in 1915. Sharp Corporation was previously the fifth-largest television manufacturer in the world, after Samsung, LG, Sony, and Panasonic. Since 2000, Sharp has heavily invested in LCD panel manufacturing plants; Kameyama in 2004, Sakai in 2009. The Sakai plant is still the only 10th generation LCD manufacturing plant on the globe and best fit for production of 60 inch or larger panels. However, the 2008 financial crisis and strong Yen significantly lowered world demand for Japanese LCD panels. Furthermore, the switch to digital TV broadcasting was virtually completed in Japan by the middle of 2011. Via Japanese government issued coupons for digital TV sets, consumers were encouraged to purchase digital TV sets until March 2011. This hit the Japanese LCD TV market, reducing it almost by half from 2010. All of those events strongly hit Sharp's LCD business. As the result, the Sakai LCD plant suffered a reduced operating rate until Fall 2012. 2012 was the 100th anniversary for Sharp but it announced the worst financial record in its history, with a loss of 376 billion yen in April 2012. In September, Sharp announced job cuts. In 2014, Sharp was able to stem losses and deliver a positive net income for its first quarter results. Wikipedia.


Time filter

Source Type

Patent
Sharp Corporation | Date: 2017-05-10

Pharmaceutical compositions suitable for oral administration in solid dosage forms are described. The compositions comprise an effective amount of a drug compound in the form of a salt, wherein the drug salt is characterized by conversion to a less soluble form of the drug compound under certain pH conditions, and an anti-nucleating agent.


Patent
Sharp Corporation | Date: 2017-03-15

The present invention relates to compounds of formula I that are metallo--lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with -lactam antibiotics for overcoming resistance.


Patent
Sharp Corporation | Date: 2017-02-08

Compounds of Formula I are described: wherein R1 and R2 are defined herein. The compounds of Formula I are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV, and the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.


A compound of Formula II or a pharmaceutically acceptable salt thereof, are capable of modulating the bodys production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula II, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula II or a pharmaceutically acceptable salt thereof.


Patent
Sharp Corporation | Date: 2017-01-30

A novel process is provided for the efficient preparation of an asymmetric compound of structural formula I: comprising a copper-catalyzed, carbon-nitrogen cross-coupling step. The process described as part of the present invention can be used to manufacture poly (ADP-ribose) polymerase (PARP) inhibitors, which may be useful for the treatment of cancer. In particular, the present invention describes a process for the manufacture of the PARP inhibitor, 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide.


Patent
Sharp Corporation | Date: 2017-04-05

The present invention relates generally to the use of gene mutations, whose presence or absence are useful for predicting a patients response to treatment with an anti-proliferative agent, in particular a WEE1 inhibitor. The presence or absence of a mutation to the TP53 gene, can be used to predict response to treatment with a WEE1 inhibitor in a patient presenting with a cancerous condition.


Patent
Sharp Corporation | Date: 2017-01-25

Described herein are polymeric nanoparticles that comprise 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[l,2,4]-triazolo-[3,4-fJ[1,6]- naphthyridin-3-one (Compound A), or a pharmaceutically acceptable salt thereof, and methods of making and using such nanoparticles.The nanoparticle comprises about 50 to about 99.8 weight percent of a diblock poly(lactic) acid-poly(ethylene)glycol copolymer or a diblock poly(lactic acid-co-glycolic acid)-poly(ethylene)glycol copolymer, wherein the total amount of poly(ethylene)glycol in the nanoparticle is about 10 to about 30 weight percent poly(ethylene)glycol and about 0.2 to about 30 weight percent of Compound A.


Patent
Sharp Corporation and MSD R & D China Co. | Date: 2017-01-18

The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.


Patent
Sharp Corporation | Date: 2017-01-04

The instant invention provides for novel lipid nanoparticle (LNP) formulations, containing cationic lipids, for use as vaccine adjuvants and/or as antigen delivery systems. It is an object of the instant invention to provide LNP formulations that demonstrate enhancements in humoral and cellular immunogenicity of vaccine antigens, particularly subunit vaccine antigens, when utilized alone or in combination with immunostimulatory agents (e.g. small molecule or oligonucleotide TLR agonists). The instant invention further identifies physical and chemical properties of the LNP formulations that can be manipulated to enhance antigen efficiency and adjuvant tolerability in vivo.


Patent
Sharp Corporation and Mochida Pharmaceutical Co. | Date: 2017-02-22

In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

Loading Sharp Corporation collaborators
Loading Sharp Corporation collaborators